为揭示3-芳基香豆素衍生物3-(4′-羟基苯基)-6-羟基香豆素(SJ-6)对抗血管钙化的作用机制,采用晚期糖基化终产物(AGEs)对人体主动脉血管平滑肌细胞(HCASMCs)进行钙化诱导并通过茜素红染色及定量进行钙化鉴定。分别检测了化合物SJ-6对碱...为揭示3-芳基香豆素衍生物3-(4′-羟基苯基)-6-羟基香豆素(SJ-6)对抗血管钙化的作用机制,采用晚期糖基化终产物(AGEs)对人体主动脉血管平滑肌细胞(HCASMCs)进行钙化诱导并通过茜素红染色及定量进行钙化鉴定。分别检测了化合物SJ-6对碱性磷酸酶(ALP)活力、细胞增殖率、钙含量、总活性氧(ROS)、超氧化物歧化酶(SOD)、AGEs、肿瘤坏死因子-α(TNF-α)、白细胞介素6(1L-6)、白细胞介素β(1L-β)、成骨相关转录因子2 m RNA(Runx2 m RNA)、晚期糖基化终产物受体(RAGE)、核因子κB(NF-κB)、NADPH氧化酶-1(NOX-1)、蛋白激酶C(PKC)、蛋白激酶B(AKT)、p38丝裂原活化蛋白激酶(p38 MAPK)、α-平滑肌肌动蛋白(SMA-α)蛋白表达的影响。根据研究结果发现化合物SJ-6可明显降低钙化细胞模型中AGEs含量、ALP活性、细胞内钙离子含量、ROS含量、Runx2 m RNA以及炎症因子TNF-α、1L-6和1L-β的含量(P<0.05),并升高SOD的含量(P<0.01),这些作用与阳性对照药氨基胍盐酸盐(AGH)相似。进一步对化合物SJ-6进行深入的药理机制研究,发现化合物SJ-6能够明显抑制钙化细胞模型中关键信号蛋白RAGE、NF-κB、NOX-1、PKC、Akt、p-p38等蛋白的表达(P<0.01),并增加平滑肌动蛋白SMA-α的表达(P<0.01),通过抑制氧化应激和AGEs/RAGE、Akt/PKC及NF-κB信号通路的表达抑制血管钙化,提示化合物SJ-6有望成为治疗血管钙化的新型药物。展开更多
Labeling analysis of three neuropeptides（Met-enkephalin, Leu-enkephalin, and neurotensin） with 7-methoxycoumarin-3-carboxylic acid N-succinimidyl ester（MCSE） was investigated. The experimental conditions for label...Labeling analysis of three neuropeptides（Met-enkephalin, Leu-enkephalin, and neurotensin） with 7-methoxycoumarin-3-carboxylic acid N-succinimidyl ester（MCSE） was investigated. The experimental conditions for labeling reaction and HPLC analysis of the neuropeptide derivatives were optimized. It was found that the labeling reatction could be achieved at 37 ℃ for one hour in H3BO3-NaCl-Na2B4O7 buffer（pH=8.3） with a labeling ratio of about 80%. The derivative mixture from the three peptides can be separated in a 40 min linear gradient from 60% to 20% of solvent A（100 mmol/L sodium acetate, pH=5.0） and from 40% to 80% of solvent B[60%（volume fraction） acetonitrile in water]. The resulting labeled products were also confirmed by MALDI-TOF-MS analysis. Compared with the native neuropeptides, the resulting labeled products have a longer absorption and fluorescence wavelengths, which is beneficial to the effective elimination of background fluorescence interference from biological matrix.展开更多
文摘为揭示3-芳基香豆素衍生物3-(4′-羟基苯基)-6-羟基香豆素(SJ-6)对抗血管钙化的作用机制,采用晚期糖基化终产物(AGEs)对人体主动脉血管平滑肌细胞(HCASMCs)进行钙化诱导并通过茜素红染色及定量进行钙化鉴定。分别检测了化合物SJ-6对碱性磷酸酶(ALP)活力、细胞增殖率、钙含量、总活性氧(ROS)、超氧化物歧化酶(SOD)、AGEs、肿瘤坏死因子-α(TNF-α)、白细胞介素6(1L-6)、白细胞介素β(1L-β)、成骨相关转录因子2 m RNA(Runx2 m RNA)、晚期糖基化终产物受体(RAGE)、核因子κB(NF-κB)、NADPH氧化酶-1(NOX-1)、蛋白激酶C(PKC)、蛋白激酶B(AKT)、p38丝裂原活化蛋白激酶(p38 MAPK)、α-平滑肌肌动蛋白(SMA-α)蛋白表达的影响。根据研究结果发现化合物SJ-6可明显降低钙化细胞模型中AGEs含量、ALP活性、细胞内钙离子含量、ROS含量、Runx2 m RNA以及炎症因子TNF-α、1L-6和1L-β的含量(P<0.05),并升高SOD的含量(P<0.01),这些作用与阳性对照药氨基胍盐酸盐(AGH)相似。进一步对化合物SJ-6进行深入的药理机制研究,发现化合物SJ-6能够明显抑制钙化细胞模型中关键信号蛋白RAGE、NF-κB、NOX-1、PKC、Akt、p-p38等蛋白的表达(P<0.01),并增加平滑肌动蛋白SMA-α的表达(P<0.01),通过抑制氧化应激和AGEs/RAGE、Akt/PKC及NF-κB信号通路的表达抑制血管钙化,提示化合物SJ-6有望成为治疗血管钙化的新型药物。
文摘Labeling analysis of three neuropeptides（Met-enkephalin, Leu-enkephalin, and neurotensin） with 7-methoxycoumarin-3-carboxylic acid N-succinimidyl ester（MCSE） was investigated. The experimental conditions for labeling reaction and HPLC analysis of the neuropeptide derivatives were optimized. It was found that the labeling reatction could be achieved at 37 ℃ for one hour in H3BO3-NaCl-Na2B4O7 buffer（pH=8.3） with a labeling ratio of about 80%. The derivative mixture from the three peptides can be separated in a 40 min linear gradient from 60% to 20% of solvent A（100 mmol/L sodium acetate, pH=5.0） and from 40% to 80% of solvent B[60%（volume fraction） acetonitrile in water]. The resulting labeled products were also confirmed by MALDI-TOF-MS analysis. Compared with the native neuropeptides, the resulting labeled products have a longer absorption and fluorescence wavelengths, which is beneficial to the effective elimination of background fluorescence interference from biological matrix.
